Of note, CRC is one of the first human cancer where a stringent correlation was found between tumor infiltrating CD8+ T cells and clinical outcome [18], thus supporting the rationale for evaluating the efficacy of immunotherapy protocols in this neoplastic disease. The gene discussed is CD8A; the disease is colorectal carcinoma.